Month: March 2024

Iridex Reports Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on March 26, 2024. Posted in Earnings Releases And Operating Results.

Advances strategic review to unlock shareholder value MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 30, 2023, and provided a business update. Fourth Quarter 2023 Results & Recent HighlightsGenerated total revenue of $12.5 million, compared to $15.2 million in the prior year period Cyclo G6® product family revenue in the fourth quarter of $3.0 million, compared to $4.2 million in the prior year periodSold 12,700 Cyclo G6 probes, compared to 16,400 in the prior year quarter Sold 35 Cyclo G6 Glaucoma Laser Systems in the fourth...

ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

Written by Customer Service on March 26, 2024. Posted in Earnings Releases And Operating Results.

PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business HighlightsGenerated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022. The quarter marked the eighth (8th) sequential quarter of record revenues. Continued focus on implementing reductions in operating expenses. Operating expenses, excluding cost of revenue, decreased over 8% compared to operating expenses reported for the second quarter of 2024 and decreased nearly 19% as...

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

Written by Customer Service on March 26, 2024. Posted in Earnings Releases And Operating Results.

On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024 Demonstrated the versatility of Korro’s RNA editing platform by generating de-novo protein variants via multiple targets in non-human primates (NHPs) Demonstrated greater than 50% editing using GalNAc conjugates in the liver with subcutaneous administration in a preclinical mouse model Ended 2023 with a strong balance sheet of $166 million of cash and cash equivalents, including $117 million of proceeds from a successful private financing completed in November 2023 Cash runway into 2026, which enables key readouts for KRRO-110 and progression of additional pipeline candidatesCAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical...

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Written by Customer Service on March 26, 2024. Posted in Earnings Releases And Operating Results.

CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination with pembrolizumab in 2H 2024 CAB-ROR2 (BA3021) Phase 2 melanoma and squamous cell carcinoma of the head and neck (SCCHN) clinical trials fully enrolled; on track for data readouts in 2Q 2024 CAB-AXL (BA3011) Phase 2 potentially registrational study in undifferentiated pleomorphic sarcoma (UPS) on track for enrollment completion of approximately 20 patients in April with anticipated FDA meeting for guidance on the remaining portion of the potentially registrational trial in 2H 2024 CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study on track with full data readout anticipated in 2H 2024; potential initiation of Phase 2 study in 2H 2024 Cash...

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Written by Customer Service on March 26, 2024. Posted in Earnings Releases And Operating Results.

Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Profile Luxeptinib G3 Formulation Achieves Desired Levels and Positions for Future Trials Conference Call and Webcast at 5:00 pm ET TodaySAN DIEGO and TORONTO, March 26, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months and year ended December 31, 2023, and provided a corporate update. “The data we have generated from tuspetinib thus far – as a single agent and in combination therapy with venetoclax in relapsed and refractory AML – have demonstrated...

Subsea 7 S.A. notification of major holding

Written by Customer Service on March 26, 2024. Posted in Public Companies.

Luxembourg – 26 March 2024 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced that, on 26 March 2024, Barclays Capital Securities Limited1 informed the Company that it recently crossed above the 5% threshold (at 5.11%) provided for by Luxembourg’s Transparency Law of 11 January 2008 on transparency requirements for issuers of securities as amended (the “Transparency Law”).On 19 March 2024 the total number of voting rights in the Company according to Article 8 and 9 of the Transparency Law attached to shares held by Barclays was 2,272,013 representing 0.74% of the voting rights in the Company On 19 March 2024 the total number of voting rights in the Company attached to financial instruments with similar economic effect according to Article 12 (1) (a) of the Transparency Law (right to recall) were 12,487,791 representing 4.10%...

Ninepoint Partners Announces March 2024 Cash Distributions for ETF Series Securities

Written by Customer Service on March 26, 2024. Posted in Dividend Reports And Estimates.

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) — Ninepoint Partners LP (“Ninepoint Partners”) today announced the March 2024 cash distributions for its ETF Series securities. The record date for the distributions is March 28, 2024 for Ninepoint High Interest Savings Fund and April 1, 2024 for Ninepoint Diversified Bond Fund, Ninepoint Alternative Credit Opportunities Fund, Ninepoint Energy Income Fund and Ninepoint Target Income Fund. All distributions are payable on April 8, 2024. The per-unit March distributions are detailed below:Ninepoint ETF Series Ticker Distribution per unit Notional Distribution per unit CUSIPNinepoint Diversified Bond Fund NBND $0.04662 $0.00000 65443H100Ninepoint High Interest Savings Fund NSAV $0.22948 $0.00000 65443X105Ninepoint Alternative Credit Opportunities Fund NACO $0.07861 $0.00000 65443Q100Ninepoint...

Surgery Partners, Inc. Announces Pricing of New Senior Notes Offering

Written by Customer Service on March 26, 2024. Posted in Public Companies.

BRENTWOOD, Tenn., March 26, 2024 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) today announced that its wholly-owned subsidiary, Surgery Center Holdings, Inc. (the “Issuer”), priced $800,000,000 aggregate principal amount of its 7.250% senior unsecured notes due 2032 (the “Notes”) in a previously announced private offering exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The offering is expected to close on April 10, 2024, subject to certain customary closing conditions. The Notes will be guaranteed (the “Guarantees”) on a senior unsecured basis by each domestic wholly-owned subsidiary of the Issuer that guarantees its obligations under its senior secured credit facilities. Surgery Partners intends to use the net proceeds...

Abcourt Closes a First Tranche of the Private Placement of Units Previously Announced, for an Amount of $1,436,234

Written by Customer Service on March 26, 2024. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ROUYN-NORANDA, Quebec, March 26, 2024 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) announces that it has completed a first closing of the non-brokered private placement announced on March 12, 2024, for gross proceeds of $1,436,234, representing 28,724,688 units of the Corporation (the “Units”), at a price of $0.05 per Unit (the “Offering”). Each Unit consists of one common share of the Corporation (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at a price of $0.06 for a period of 36 months following the closing date of the Offering. Abcourt paid finder’s fees in an amount of $500 and issued...

JDE Peet’s completes transaction to manufacture, market and sell Caribou-branded consumer and foodservice coffee products

Written by Customer Service on March 26, 2024. Posted in Public Companies.

PRESS RELEASE Amsterdam, 26 March 2024 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee and tea company by revenue, today announced the completion of the previously announced transaction under which the company has been granted a long-term global license to manufacture, market and sell Caribou consumer and foodservice coffee products, excluding Caribou coffeehouses. The transaction provides JDE Peet’s a strong platform to expand its premium coffee portfolio in the United States, the largest coffee market in the world, in which the company already sells and distributes Peet’s coffee, Stumptown, Intelligentsia and L’OR coffee. Under the terms of the agreement, JDE Peet’s has acquired Caribou’s coffee roasting operations in Minneapolis, Minnesota. The two companies have also entered into a long-term strategic arrangement...

Month: March 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals